-27%

est. 2Y upside i

HealthcareSeries D+

Rank

#3226

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Ultima Genomics presents a moderate upside opportunity (21.2% expected return) for a job seeker, driven by its disruptive, cost-reducing sequencing technology and strong recent growth in installed base and contracted revenue.

Last updated: March 10, 2026

Bull (30%)+100%

Ultima Genomics' proprietary sequencing architecture gains significant market share by further reducing sequencing costs and expanding its installed base, particularly with the UG200™ series and Solaris 2.0 workflows. Strategic partnerships and regulatory approvals for clinical applications drive revenue to $300M+ by 2028, justifying a $2.0B valuation.

Base (32%)+20%

Ultima Genomics continues to grow its installed base and reagent sales, reaching ~$180M in revenue by 2028, but faces sustained competitive pressure from incumbents like Illumina and Pacific Biosciences. The company achieves a modest valuation increase to $1.2B, providing limited upside for common shareholders due to the preference stack.

Bear (38%)-40%

Aggressive pricing and new product launches from dominant incumbents, particularly Illumina, stifle Ultima Genomics' market penetration and pricing power. Regulatory delays or slower-than-expected adoption of new platforms lead to revenue stagnation below $150M. A down round or acquisition at $0.6B results in minimal or no return for common stock due to the $600M liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

severe

Funding Intensity

60%

Investors hold $600M in liquidation preferences ahead of common stock, meaning common shareholders may receive little to nothing in an exit at or below the current $1.0B valuation.

Dilution Risk

high

Given the high capital intensity and significant funding raised, future dilution from additional funding rounds is a considerable risk for common shareholders.

Secondary Liquidity

limited

While secondary marketplaces exist (e.g., Forge, EquityZen, Nasdaq Private Market), liquidity is limited to accredited investors and subject to company policies.

Other — 13 roles

View all 13 open roles at Ultimagenomics →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Ultimagenomics's data — designed to show you've done your homework.

  • 1

    “Given Illumina's dominant market position and recent product developments, how does Ultima Genomics plan to sustain its competitive advantage and pricing power, especially with the launch of the UG200™ series and Solaris 2.0 workflows?”

  • 2

    “With ~$103M in revenue and a $1.0B valuation, what are the key milestones and growth drivers the company is targeting to achieve a significant increase in valuation over the next 2-3 years, particularly considering the high capital intensity of the business?”

  • 3

    “Considering the $600M in total funding and the current $1.0B valuation, what is the company's strategy for managing the preference stack and ensuring meaningful liquidity for common shareholders in a potential IPO or acquisition?”

Community

Valuation Sentiment

Our model estimates -27% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.